Refractory congestive heart failure: when the solution is outside the heart.
Vicente PerniasMiguel GonzálezGema MinanaJose Luis GórrizIsabel JuanFrancisco J ChorroJuan SanchisJulio NunezPublished in: ESC heart failure (2019)
Refractory congestive heart failure is associated with an ominous prognosis in which the treatments strategies remain scarce and not well validated. In the last years, continuous ambulatory peritoneal dialysis (CAPD) has emerged as a therapeutic alternative in this subset of patients. So far, it has been associated with a significant improvement in functional capacity and quality of life, together with a striking reduction in the risk of readmissions. We present the case of an elderly patient with severe left ventricular dysfunction and severe mitral and tricuspid regurgitation who presents recurrent admissions for anasarca. After its inclusion in a CAPD programme, the patient experienced a marked clinical and biochemical improvement despite the persistence of cardiac abnormalities. CAPD onset translates into greater sodium removal. We want to emphasize the usefulness of this therapy in the management of volume excess in patients with refractory heart failure and renal failure promoting a greater sodium removal compared with traditional diuretic strategies.
Keyphrases
- heart failure
- left ventricular
- end stage renal disease
- peritoneal dialysis
- aortic stenosis
- chronic kidney disease
- mitral valve
- cardiac resynchronization therapy
- ejection fraction
- acute heart failure
- left atrial
- hypertrophic cardiomyopathy
- atrial fibrillation
- acute myocardial infarction
- case report
- aortic valve
- newly diagnosed
- early onset
- blood pressure
- transcatheter aortic valve replacement
- oxidative stress
- stem cells
- mesenchymal stem cells
- coronary artery disease
- bone marrow